Nearly 90% of procedures were bypass surgeries; hospital reports below 20% blood transfusion rate and less than 1% 30-day mortality, but comparative data on long-term outcomes remains undisclosed.

BENGALURU, November 20, 2026: While Sakra World Hospital has announced the completion of 1,000 robotic-assisted cardiac surgeries, the milestone also raises important questions about patient safety, treatment costs, surgical risks and the actual long-term benefits of robotic technology compared with conventional heart surgery.
The hospital, which conducted these procedures under the leadership of Dr. Adil Sadiq, Director and Head of Cardio Thoracic and Vascular Surgery, reported that nearly 88–90% of the surgeries involved coronary artery bypass grafting (CABG).
Although robotic-assisted surgery is being promoted as a minimally invasive alternative to conventional open-heart surgery, the announcement does not provide a detailed comparison of clinical outcomes between robotic and traditional surgical procedures. This leaves patients and their families with important questions about whether the advanced technology delivers significantly better outcomes or primarily offers an alternative surgical approach.
Technology alone does not guarantee better outcomes
Robotic-assisted cardiac surgery uses the da Vinci surgical system, allowing surgeons to operate through small incisions between the ribs rather than opening the breastbone in selected cases.
The approach may reduce surgical trauma, post-operative pain and hospitalisation time. However, not every cardiac patient is suitable for robotic surgery. The hospital itself acknowledges that treatment decisions depend on the patient’s anatomy, disease complexity and overall health.
This raises questions about how patients are selected, how many are found unsuitable for robotic procedures and what happens when complications require conversion to conventional open-heart surgery.
Hospitalisation and mortality figures need closer scrutiny
According to the hospital’s review of 1,000 robotic-assisted cardiac surgeries performed between July 16, 2022, and November 12, 2026, the average hospital stay was 4.34 days.
The hospital also reported a blood transfusion rate of below 20% and a 30-day mortality rate of less than 1%.
While these figures have been presented as indicators of the programme’s performance, several important details remain unclear.
The hospital has not provided a detailed breakdown of major post-operative complications, readmission rates, infections, stroke incidents, conversion to open surgery or long-term survival outcomes in its announcement.
Similarly, the blood transfusion rate of below 20% requires greater clarity about the actual number of patients who needed transfusions and the reasons behind them.
For patients facing expensive cardiac treatment, transparency on these parameters is essential before the technology is projected as a major advancement in heart care.
Affordability remains a major concern
Another important issue is the cost of robotic-assisted cardiac surgery.
Advanced robotic systems involve substantial investment in equipment, maintenance and specialised medical expertise. However, the hospital’s announcement does not disclose the average cost of these procedures or explain how robotic surgery compares financially with conventional bypass and valve surgeries.
For middle-class and economically weaker patients, the question is straightforward: Does advanced technology make quality cardiac treatment more accessible, or does it increase the financial burden on families?
The hospital also needs to clarify whether insurance coverage and cashless treatment facilities are available for all eligible patients undergoing robotic-assisted cardiac procedures.
Individual success stories cannot replace comprehensive clinical data
The hospital highlighted two patient recovery experiences, including an 84-year-old man who underwent robotic triple bypass surgery and reportedly returned to playing tennis within a month.
Another 58-year-old patient who underwent robotic mitral valve replacement reportedly showed substantial improvement in his heart failure condition during follow-up.
While these cases demonstrate encouraging individual recoveries, isolated success stories cannot establish the overall effectiveness and safety of a surgical programme.
Independent clinical evaluation, transparent complication reporting and long-term follow-up data are necessary to understand the actual benefits and limitations of robotic-assisted cardiac surgery.
Patients deserve more than milestone announcements
Sakra World Hospital Managing Director Yuichi Nagano, Deputy Managing Director Kei Iiyama and Group Chief Operating Officer Lovekesh Kumar Phasu highlighted the institution’s investment in technology, clinical expertise, teamwork and continuous improvement.
However, the real measure of medical advancement should not be the number of robotic procedures performed or the technology deployed, but the quality, safety, affordability and long-term outcomes delivered to patients.
As robotic-assisted cardiac surgery gains attention in India’s healthcare sector, hospitals must ensure that patients receive clear information about treatment alternatives, possible complications, expected recovery, financial implications and realistic clinical outcomes.
A milestone of 1,000 surgeries may be an institutional achievement, but for patients and their families, the more important questions remain: How safe is the procedure, how affordable is it, what are the long-term outcomes, and does it genuinely offer better results than conventional heart surgery?
City Today News 9341997936
